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Surface proteins play key roles in the interaction between cells and
their environment, and in pathogenic microorganisms they are the
best targets for drug or vaccine discovery and/or development. In
addition, surface proteins can be the basis for serodiagnostic tools
aiming at developing more affordable techniques for early diag-
nosis of infection in patients. We carried out a proteomic analysis of
a collection of pediatric clinical isolates of Streptococcus pneumo-
niae, an important human pathogen responsible for more than
1.5 million child deaths worldwide. For that, cultured live bacterial
cells were “shaved” with trypsin, and the recovered peptides were
analyzed by LC/MS/MS. We selected 95 proteins to be produced as
recombinant polypeptides, and printed them on an array. We
probed the protein array with a collection of patient sera to deﬁne
serodiagnostic antigens. The mass spectrometry proteomics data
correspond to those published in [1] and have been deposited to
the ProteomeXchange Consortium [2] via the PRIDE partner repo-
sitory [3] with the dataset identiﬁer PXD001740. The protein array
raw data are provided as supplemental material in this article.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
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ject areaMicrobial proteomics and immunologyype of data MS data, protein array data, tables
ow data was
acquiredProteomic analysis of “shaved” bacteria was done using a Surveyor HPLC
System in tandem with an LTQ-Orbitrap mass spectrometer (Thermo Fisher
Scientiﬁc, San Jose, USA). Protein array data were acquired with a Genepix
4000B microarray scanner (Molecular Devices Corporation, Union City, CA)ata format Raw LC/MS/MS data; ﬁltered and analyzed Excel ﬁles
xperimental
factorsA collection of 24 invasive pneumococcal clinical isolates from pneumonia
children patients was used; sera from two cohorts of children (patients
with pneumococcal disease and patients with non-pneumococcal disease
or healthy controls) were collected for subsequent protein array
hybridizationxperimental
featuresThe 24 pneumococcal clinical isolates were cultured in a chemically-deﬁned
medium and the live cells were trypsinized. The generated peptides were
analyzed by LC/MS/MS, and a set of 95 proteins was chosen for recombinant
polypeptide production and further protein array printing. The array was
probed with a set of sera from childrenata source
locationCórdoba and Sevilla, Spainata accessibility Data are available at the ProteomeXchange: PXD001740 and also pro-
vided as supplemental material within this article. All of them are related
to [1]Value of the data The “shaving” approach for identifying the “pan-surfome” of a collection of pneumococcal clinical
isolates [4,5] provides highly valuable information on the most promising surface antigens for
vaccine and/or diagnostic purposes.
 The most promising protein candidates were produced as recombinant polypeptides to construct
protein arrays.
 Sera from children patients were probed on the protein array to identify a set of immunodominant
antigens that can be used for early diagnosis of infection.
 The strategy of combining experimental proteomics identiﬁcation of surface proteins for protein
array development proved to be very useful for its use in clinics with different utilities: diagnostics,
epidemiological surveillance or vaccine discovery.1. Data
Supplemental Dataset 1 contains all the raw protein array reads for patient and control sera, using
both human anti-IgM and anti-IgG antibodies.
Table S1 shows the processed data (mean7SD) of the IgG Signal Mean Intensity (SMI) values of all
sera used in the protein array hybridization measurements.
Table S2 shows the processed data (mean7SD) of the IgM Signal Mean Intensity (SMI) values of
all sera used in the protein array hybridization measurements.
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2.1. Experimental design
A scheme for the experimental design from which the data were obtained is shown in Fig. 1.
A collection of 24 clinical isolates from the Gram-positive human pathogen Streptococcus pneumoniae,
also known as pneumococcus, were subjected to proteomic analysis to identify the set of the most
prominent and abundant surface proteins (the “surfome”) in all or most of the analyzed isolates (the
“pan-surfome”), following a strategy ﬁrst described in [6], consisting of “shaving” the live cultured
cells with trypsin. Then, the fractions of peptides generated from the surface-exposed and/or surface-
attached proteins are redigested with trypsin as ﬁrst described in [7] and optimized for pneumo-
coccus in [4], to be analyzed by LC/MS/MS. The whole raw and processed data derived from those
analyses, as further described in Section 3, can be found in the PRIDE repository with the dataset
identiﬁer PXD001740. The protein identiﬁcations were rearranged according to their subcellular
localization and GO predictions, to select those predicted surface proteins and/or with assigned
surface-linked functions present in a high proportion of clinical isolates. From this list, 95 proteins
were ﬁnally selected for production of recombinant polypeptides according to the criteria already
described in [1]. Also 9 predicted cytoplasmic proteins were selected, as they were identiﬁed very
consistently and have been described to be surface-associated in numerous organisms [8]. Then, the
95 puriﬁed recombinant polypeptides were printed on a protein array and probed with a collection of
human sera. After comparison of the “patient” and “control” groups (see below in Section 3), the
potential serodiagnostic biomarkers were deﬁned as those with at least a 1.5-fold difference in
seroresponse between both groups.Fig. 1. Flowchart of experimental design, data collection and processing.
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3.1. Human sera and ethical statement for their use
All human sera were obtained from patients admitted to Hospital Universitario Infantil Virgen del
Rocío (HUIVR), Seville, Spain, and collected from children o14 years old. Sera were drawn either from
patients with a diagnosis of pneumococcal pneumonia (the “patient” group), or from healthy children
or patients affected by other pathologies different from pneumococcal pneumonia (the “control”
group). Written informed consent was obtained from parents or legal guardians of participating
children, for sera to be used within the project in which this work was designed, according to the
principles expressed in the Declaration of Helsinki.
3.2. Bacterial culture and surface “shaving”
Twenty-four pneumococcal isolates from human patients with pleural empyema were kept, grown
and “shaved” for surface protein identiﬁcation as already described [4,5].
3.3. LC/MS/MS analysis
All analyses were performed as described [4,5], using a Surveyor HPLC System in tandem with an
LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientiﬁc, San Jose, USA) equipped with nanoelec-
trospray ionization interface (nESI). MS data (Full Scan) were acquired in the positive ion mode over
the 400–1500m/z range. MS/MS data were acquired in dependent scan mode, selecting automatically
the ﬁve most intense ions for fragmentation, with dynamic exclusion set to on.
3.4. Database searching for protein identiﬁcation
Tandem mass spectra were extracted using Thermo Proteome-Discoverer 1.0 (Thermo Fisher
Scientiﬁc). Charge state deconvolution and deisotoping were not performed. All MS/MS samples were
analyzed using Sequest (Thermo Fisher Scientiﬁc, version v.27), as described [1]. The raw data were
searched against an in-house joint database containing 30,673 protein sequences from all the 17 full
sequenced and annotated S. pneumoniae strains available at the UniProtKB site at the moment of the
database construction (UniProt taxonomic IDs 189423, 488221, 574093, 561276, 516950, 373153,
487214, 488222, 488223, 171101, 487213, 525381, 760887, 512566, 170187, 1069625, and 760888, all
of them in their versions of May 5, 2014).
3.5. In silico protein mining and functional annotation
Primary predictions of subcellular localization were assigned by using the web-based algorithm
LocateP (http://www.cmbi.ru.nl/locatep-db/cgi-bin/locatepdb.py). They were contrasted by several
feature-based algorithms: TMHMM 2.0 (http://www.cbs.dtu.dk/services/TMHMM-2.0) for searching
transmembrane helices; SignalP 3.0 (http://www.cbs.dtu.dk/services/SinalP) for type-I signal pep-
tides: those proteins containing only a cleavable type-I signal peptide as featured sequence were
classed as secreted; LipoP (http://www.cbs.dtu.dk/services/LipoP) for identifying type-II signal pep-
tides, which are characteristic of lipoproteins. GO annotations were retrieved from the UniProt
Knowledgebase (http://www.uniprot.org/) and annoted using a webserver from the University of
Adelaide (http://genomes.ersa.edu.au/BacteriaGO/submissions.php).
3.6. Production of recombinant proteins
Recombinant proteins were produced as double fusion fragments containing an N-terminal GST
fragment and a C-terminal His-tag using the pSparks I vector (Canvax Biotech, Córdoba, Spain), and
expressed in Escherichia coli BL21, as described [1] and according to manufacturers’ instructions.
A. Olaya-Abril et al. / Data in Brief 6 (2016) 917–922 921Brieﬂy, recombinant products were puriﬁed by Ni2þ–agarose afﬁnity chromatography from the E. coli
intracellular fraction, dialyzed against PBS and used for protein array printing.3.7. Protein array construction and probing
Afﬁnity-puriﬁed recombinant proteins were printed on glass slides in quintuplicate (6 ng/spot) as
detailed in [1] with split pins (44 pin tool) using a robotic array spotter (Genomic Solutions,
BioRobotics MicroGrid II 610). Each component was prepared at 250 μg/ml in printing buffer (150 mM
phosphate, pH 8.5, 0.01% sarkosyl) onto Nexterion Slide H 3-D glass slides. Eight complete arrays were
printed on each slide. Probing with human sera was carried out in duplicate for each serum sample.
Slides were assembled on 16-well slide holders (Nexterion Slide H MPX 16) and 45 ml of a dilution of
different sera from the test set (1:200 in PBST) were incubated for 1 h protected from light at room
temperature. The different samples were incubated with anti-human IgG-Cy3 (1:1000) or anti-
human IgM-Cy5 (1:200), covered tightly with a seal strip, and incubated for 1 h at room temperature.
To process the array data, the slides were scanned with a Genepix 4000B microarray scanner
(Molecular Devices Corporation, Union City, CA) at photomultiplier voltage settings that no saturated
pixels were obtained. Image analysis was carried out with Genepix Pro 4.1 analysis software (Mole-
cular Devices Corporation). Local background subtraction was performed and corrected median
feature intensity was used for initial data processing.3.8. Protein array data analysis
For analysis of antibody binding to recombinant fragments on the microarray, local background
subtraction from 10 surrounding spots was performed and corrected median ﬂuorescence intensity
was used for initial data processing. Then, the mean background signal of negative controls was
substracted from each raw spot value after sera hybridization. Negative controls represented hybri-
dizations of non-pneumococcal proteins and buffer spots with sera and secondary antibodies. Both in
non-pneumococcal proteins and buffer positions, no reaction with human sera was observed. After
background substraction, negative or zero values were assigned a net value of 0. Then, outlier values
for each spot were removed. The two different hybridizations for each serum were averaged to report
the signal mean intensity (SMI) values, and the mean and standard deviation (SD) were obtained from
the 5 printed spots per protein in each patient and control groups. Finally, data normalization by
background was carried out using Microsoft Excel as described [9].Acknowledgments
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